Artificial Sweeteners Linked to Higher BMI, Cardiometabolic Risk

Patrice Wendling

July 31, 2017

WINNIPEG, MB — A new meta-analysis and systematic review finds mixed evidence to support use of artificial sweeteners for weight loss and suggests routine consumption may be associated with long-term weight gain and an increased risk of cardiometabolic disease[1].

"People are generally consuming nonnutritive sweeteners (NNS) believing they are a 'healthy choice,' but this may not be true," study author Dr Meghan Azad (University of Manitoba, Winnipeg) told | Medscape Cardiology in an email.

"More important, our results send a strong message to researchers and research funding bodies that more studies are needed to understand the long-term health impacts of artificial sweeteners."

The lack of studies looking at long-term effects is surprising, given that more than 40% of adult Americans regularly consume NNS, such as aspartame, sucralose, and stevia, she said. In addition, studies measuring NNS in blood and urine show that many people who report not using NNS are unknowingly consuming these sweeteners in foods.

The study, published July 17, 2017 in CMAJ, pooled results from seven randomized controlled trials with 1003 participants (median follow-up 6 months) and 30 cohort studies with 405,907 participants (median follow-up 10 years).

In participants who were obese or overweight, two longer trials showed significant weight loss with NNS over 16 to 24 months and three shorter trials showed no effect with NNS use over 6 months. Both of the longer-term trials, however, were industry sponsored, and all five trials were at high risk of bias, the authors noted.

Two trials involving mildly hypertensive patients who were taking stevioside capsules and one in overweight participants showed no significant effect on BMI over 6 to 24 months (mean difference -0.37 kg/m2; 95% CI -1.10 to 0.36).

Large cohort studies with longer follow-up, however, showed that high NNS intake was significantly associated with modest long-term gains in body weight, BMI, and waist circumference.

In addition, high NNS intake was associated with higher risks of hypertension (hazard ratio [HR] 1.13, 95% CI 1.06–1.20), stroke (risk ratio [RR] 1.14, 95% CI 1.04–1.26), cardiovascular events (RR 1.32, 95% CI 1.15–1.52), and incident type 2 diabetes (RR 1.14, 95% CI 1.05–1.23).

Notably, there were no data from the trials to confirm these observations, and the increased risk for type 2 diabetes found in nine cohort studies was attenuated (RR 1.07, 95% CI 0.97–1.18) after imputing missing studies, suggesting potential publication bias, the authors write.

Dr Lawrence Cheskin (Johns Hopkins Weight Management Center, Baltimore, MD) said, "Even though they point to some observational studies and say there is more diabetes, there's no experimental evidence that that occurs in humans. Nor heart disease."

He feels it is unlikely  that artificial sweeteners directly cause heart disease. "It may be associated with people who have somewhat higher risks of heart disease because they're heavier and have bad habits and are drinking diet soda to make up for the other things they're doing that aren't so good," he speculated.

In addition to the confounding factor of selection bias, Cheskin pointed out that the seven randomized trials were in small numbers of people followed for relatively short periods of time and looked only at certain types of sweeteners available at the time and in beverages, not in other foods. In four of the trials, participants using NNS were also on a weight-loss program.

For its part, the Academy of Nutrition and Dietetics, the largest organization of food and nutrition professionals in the US, says NNS play a role in weight and blood glucose control.

"I think there's certainly nothing in this paper that would reverse that recommendation," Cheskin said. "It doesn't add truth, it just adds a few more observational studies."

Dr Matthew Pase (Boston University School of Medicine, MA) commented, "I don't think the evidence is very strong with regard to the harder cardiovascular outcomes. Certainly there needs to be more research done there."

His own group recently reported that participants in the Framingham Heart Study who drank one or more cans of artificially sweetened diet soda daily vs those who never drank diet soda were at three times increased risk of stroke or dementia.

"But obviously this was an observation, and like the observational studies we're discussing, it's hard to know what's driving the association," he said. "Is it due to reverse causality: do people who are unhealthy simply gravitate toward artificial sweeteners or do artificial sweeteners actually have some detrimental effect on health?"

Pase said that NNS consumption should be tracked from an early age in cohort and observational studies rather than in already-unhealthy people and that more mechanistic and animal studies are needed to understand the mechanisms that could contribute to the negative effects of NNS seen in observational studies.

Azad said much of her research is focused on the gut microbiome and that recent studies have shown artificial sweeteners can disrupt the gut microbiome in rats and adult humans. Thus, "routinely consuming artificial sweeteners may be selecting for an 'obesogenic' microbiome."

There is also some evidence that routine consumption may confuse and "reprogram" metabolism in a way that favors weight gain, insulin resistance, and glucose intolerance, she said.

Consuming NNS may also promote a sweet tooth or give consumers a sense of "permission" to eat higher-calorie foods because they "saved" on calories with their diet drink, for example.

The Calorie Control Council, an association representing the low- and reduced-calorie food and beverage industry, said in a statement the study paints low-calorie sweeteners with "too broad a brush" and that the "researchers admit that less than 50% of the cohort studies controlled for ethnicity or socioeconomic status, which are both known risk factors for obesity and cardiometabolic illness."

Azad reported no relevant financial relationships. Disclosures for the coauthors are listed in the paper. Cheskin reported serving on the scientific advisory boards of Medifast and Pressed Juicery. Pase is funded by the National Health and Medical Research Council.

Follow Patrice Wendling on Twitter: @pwendl. For more from | Medscape Cardiology, follow us on Twitter and Facebook.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.